Thrombin generation in a woman with heterozygous factor V Leiden and combined oral contraceptives: A case report. Issue 3 (2nd March 2020)

• Record Type: Journal Article
• Authors: Zermatten, Maxime G.; Bertaggia Calderara, Debora; Aliotta, Alessandro; Alberio, Lorenzo
• Is Part Of: Research and practice in thrombosis and haemostasis. Volume 4:Issue 3(2020)
• Page Start: 429
• Page End: 432
• Publication Date: 2020-03-02
• Subjects: contraception -- factor V -- thrombin -- thromboembolism -- thrombosis -- venous; Thrombosis -- Periodicals; Hemostasis -- Periodicals; 616.135005
• DOI: 10.1002/rth2.12318
• Languages: English
• ISSNs: 2475-0379

Abstract

Abstract: Combined oral contraceptives and factor V Leiden mutation are multiplicative risk factors for venous thromboembolism. However, it remains unknown whether this multiplicative effect is reflected in thrombin generation assays. We report here the evolution of the thrombin generation profile while taking combined oral contraceptives and after their discontinuation in a woman with heterozygous factor V Leiden mutation. The proband exhibited a distinctly prothrombotic thrombin generation profile including markedly decreased thrombomodulin (TM) sensitivity, compared to the control population. This profile possibly reflected a high thrombotic risk. After discontinuation of combined oral contraceptives, thrombin generation and TM sensitivity improved greatly, leaving only a slightly prothrombotic profile. Therefore, the multiplied thrombotic risk occurring with simultaneous combined oral contraceptives and factor V Leiden mutation is reflected by a thrombin generation assay performed without and with TM. This could be a promising tool to identify women taking combined oral contraceptives at high risk for venous thromboembolism. Further studies are needed to verify this hypothesis.